Singapore markets close in 4 hours 45 minutes

Cytosorbents Corporation (CTSO)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.8407+0.0307 (+3.79%)
At close: 04:00PM EDT
0.8112 -0.03 (-3.51%)
After hours: 07:22PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.8100
Open0.8318
Bid0.8088 x 100
Ask0.8799 x 100
Day's range0.8100 - 0.8642
52-week range0.7820 - 4.2900
Volume105,212
Avg. volume100,367
Market cap45.655M
Beta (5Y monthly)0.59
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • GlobeNewswire

    CytoSorbents to Report First Quarter 2024 Operating and Financial Results

    PRINCETON, N.J., April 26, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report first quarter 2024 operating and financial results after the market close on Thursday, May 9th, 2024. CytoSorbents’ management will host a live conference call and presentation webcast and a question and answer session starting at 4:30PM EDT the same day. Webcast D

  • GlobeNewswire

    STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting

    PRINCETON, N.J., April 17, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, today announced that topline results from its pivotal U.S. and Canadian Safe and Timely Antithrombotic Removal of Ticagrelor (STAR-T) randomized controlled trial will be featured as a late-breaking clinical trial presentation a

  • GlobeNewswire

    CytoSorbents Reports Fourth Quarter and Full Year 2023 Results

    STAR-T trial results selected for a Breakout Presentation at the American Association of Thoracic Surgery Annual Meeting in late-April 2024 CytoSorbents intends to submit DrugSorb-ATR for regulatory approval to U.S. Food & Drug Administration (FDA) and Health Canada this year CytoSorb core sales increased approximately 10% year-over-year 2023 Product gross margins increased to 72% Cumulative CytoSorb treatments surpassed 228,000 PRINCETON, N.J., March 14, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Co